Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Naunyn-Schmiedeberg's Archives of Pharmacology

• Publication date

  2011-03-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00210-011-0623-0PMID 21448567
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lipophilic statins prevent matrix metalloproteinase-mediated cartilage collagen breakdown by inhibiting protein geranylgeranylation

  2010influential reference
• Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology.

  2010cited by this paper
• Evidence for the involvement of matrix metalloproteinases in the cardiovascular effects produced by nicotine.

  2010cited by this paper
• Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling.

  2010cited by this paper
• A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins.

  2010cited by this paper
• Atorvastatin Modulates Matrix Metalloproteinase Expression, Activity, and Signaling in Abdominal Aortic Aneurysms

  2010cited by this paper
• Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability.

  2010influential reference
• Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix.

  2010cited by this paper
• Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.

  2009cited by this paper
• Statins inhibit matrix metalloproteinase release from human lung fibroblasts

  2009cited by this paper
• Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.

  2009cited by this paper
• Chitosan oligosaccharides attenuate hydrogen peroxide-induced stress injury in human umbilical vein endothelial cells.

  2009cited by this paper
• Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension.

  2009cited by this paper
• Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats.

  2008cited by this paper
• Regulation of matrix metalloproteinase gene expression

  2007cited by this paper
• Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene.

  2007influential reference
• Protective effects of atorvastatin in rat models of acute pulmonary embolism: Involvement of matrix metalloproteinase‐9*

  2007influential reference
• Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.

  2007cited by this paper
• Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature

  2007influential reference
• Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-kappaB activation.

  2006cited by this paper
• Production of matrix metalloproteinases in human cultured mast cells: involvement of protein kinase C-mitogen activated protein kinase kinase-extracellular signal-regulated kinase pathway.

  2006cited by this paper
• The role of matrix metalloproteinase inhibitors in ischemia-reperfusion injury in the liver.

  2006cited by this paper
• eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite.

  2006cited by this paper
• Pleiotropic effects of statins.

  2005cited by this paper
• Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture.

  2005cited by this paper
• A comparison of six statins on the development of intimal hyperplasia in a human vein culture model.

  2005cited by this paper
• Nitrosative stress and pharmacological modulation of heart failure.

  2005cited by this paper
• Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities.

  2005cited by this paper
• Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry

  2003cited by this paper
• Regulation of Matrix Metalloproteinase (Matrixin) Genes in Blood Vessels: A Multi-Step Recruitment Model for Pathological Remodelling

  2003cited by this paper
• An absolute role of the PKC-dependent NF-kappaB activation for induction of MMP-9 in hepatocellular carcinoma cells.

  2003cited by this paper
• Statins Inhibit Secretion of Metalloproteinases-1, -2, -3, and -9 From Vascular Smooth Muscle Cells and Macrophages

  2003influential reference
• How matrix metalloproteinases regulate cell behavior.

  2001cited by this paper
• Plasma MMP-9 - a marker of carotid plaque instability.

  2001cited by this paper
• Fluvastatin Inhibits Matrix Metalloproteinase-1 Expression in Human Vascular Endothelial Cells

  2000influential reference
• New insights into the pharmacodynamic and pharmacokinetic properties of statins.

  1999cited by this paper
• Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity.

  1999cited by this paper
• Matrix Metalloproteinases*

  1999cited by this paper
• HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages.

  1998influential reference
• Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.

  1997cited by this paper
• Molecular bases of the acute coronary syndromes.

  1995cited by this paper
• Matrix metalloproteinases and cardiovascular disease.

  1995cited by this paper
• Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin.

  1992cited by this paper
• Cell cycle-specific effects of lovastatin.

  1991cited by this paper
• This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba

  year unknowncited by this paper

• Matrix metalloproteinase-9 in hemorrhagic transformation after acute ischemic stroke (Review)

  2025cites this paper
• Coronary plaque healing: a safety net or a hazard indicator?

  2025cites this paper
• Epigenetics is involved in the pleiotropic effects of statins

  2025cites this paper
• A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease and coronary artery aneurysms

  2025cites this paper
• Coronary Artery Aneurysm or Ectasia as a Form of Coronary Artery Remodeling: Etiology, Pathogenesis, Diagnostics, Complications, and Treatment

  2024cites this paper
• SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease

  2023cites this paper
• Neuroprotective effects of Lovastatin against traumatic spinal cord injury in rats.

  2022cites this paper
• A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial

  2022cites this paper
• Molecular Mechanisms of the Cardiotoxic Action of Anthracycline Antibiotics and Statin-Induced Cytoprotective Reactions of Cardiomyocytes

  2021cites this paper
• Free P-Cresyl Sulfate Shows The Highest Association With Cardiovascular Outcome In Chronic Kidney Disease.

  2021cites this paper
• Statins: Neurobiological underpinnings and mechanisms in mood disorders.

  2021cites this paper
• Evaluation of matrix metalloproteinases and tissue inhibitors of metalloproteinases in aqueous humor of dogs with versus without naturally occurring primary angle-closure glaucoma.

  2021cites this paper
• HMG-CoA Reductase Inhibitor, Simvastatin Is Effective in Decreasing Degree of Myocarditis by Inhibiting Metalloproteinases Activation

  2021cites this paper
• Atorvastatina Atenua o Remodelamento Vascular em Camundongos com Síndrome Metabólica

  2021cites this paper
• Phenotypic modulation of smooth muscle cells and matrix metalloproteinases as targets for atherosclerotic plaque stabilization

  2020cites this paper
• [Molecular mechanisms of the cardiotoxic action of anthracycline antibiotics and statin-induced cytoprotective reactions of cardiomyocytes].

  2020cites this paper
• Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and Challenges.

  2020cites this paper
• Atorvastatin attenuates vascular remodelling in spontaneously hypertensive rats via the protein kinase D/extracellular signal‐regulated kinase 5 pathway

  2020cites this paper
• Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

  2019cites this paper
• Simvastatin pretreatment ameliorates t-PA – induced hemorrhage transformation and MMP-9/ TIMP-1 imbalance in thromboembolic cerebral ischemic rats

  2019cites this paper
• Multiple Soluble Components of the Glycocalyx Are Increased in Patient Plasma After Ischemic Stroke.

  2019cites this paper
• RhoA and Rho‐kinase inhibitors modulate cervical resistance: The possible role of RhoA/Rho‐kinase signalling pathway in cervical ripening and contractility

  2019cites this paper
• Pathologies of matrix metalloproteinase-2 underactivity: a perspective on a neglected condition 1.

  2019cites this paper
• Simvastatin pretreatment ameliorates t-PA–induced hemorrhage transformation and MMP-9/TIMP-1 imbalance in thromboembolic cerebral ischemic rats

  2019cites this paper
• Matrix metalloproteinase-3 predicts clinical cardiovascular outcomes in patients with coronary artery disease: a 5 years cohort study

  2019cites this paper
• Refractory Kawasaki disease: diagnostic and management challenges

  2019cites this paper
• PHMT_A_165935 131..139

  2019cites this paper
• Effects of Simvastatin on Augmentation Index Are Transient: Outcomes From a Randomized Controlled Trial

  2019cites this paper
• Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal

  2019cites this paper
• The rs243866/243865 polymorphisms in MMP-2 gene and the relationship with BP control in obese resistant hypertensive subjects.

  2018cites this paper
• Serum Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1 and Matrix Metalloproteinase-9/ Neutrophil Gelatinase-associated Lipocalin Complex Levels in Patients With Early-stage Diabetic Nephropathy.

  2018cites this paper
• Amino Acid Signature in Human Melanoma Cell Lines from Different Disease Stages

  2018cites this paper
• Corneal Melt after Boston Keratoprosthesis: Clinical Presentation, Management, Outcomes and Risk Factor Analysis

  2018cites this paper
• High mobility group box-1 (hmgb1) in systemic vasculitides

  2018cites this paper
• Matrix metalloproteinase-2 -735C/T polymorphism is associated with resistant hypertension in a specialized outpatient clinic in Brazil.

  2017cites this paper
• Do different tendons exhibit the same response following chronic exposure to statins?

  2017cites this paper
• The effect of estrogen on tendon and ligament metabolism and function.

  2017cites this paper
• Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease

  2017cites this paper
• Adjunctive therapies in Kawasaki disease

  2017cites this paper
• An Overview of the Pleioptropic Effects of Statins and Their Impact on Postoperative Outcomes in Cardiovascular Surgery Patients

  2017cites this paper
• Plasma concentration, genetic variation, and gene expression levels of matrix metalloproteinase 9 in Iranian patients with coronary artery disease

  2017cites this paper
• Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges.

  2017cites this paper
• Increased Circulating Tissue Inhibitor of Metalloproteinase‐2 Is Associated With Resistant Hypertension

  2016cites this paper
• Effects of atorvastatin on atrial remodeling in a rabbit model of atrial fibrillation produced by rapid atrial pacing

  2016cites this paper
• Role of Atorvastatin on Endothelial Cells and Endothelial Progenitor Cells in Cardiovascular Disease

  2016cites this paper
• Drug-Induced Tendon Disorders.

  2016cites this paper
• The role of statins in inflammatory vasculitides

  2015cites this paper
• Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: a Phase I/IIa trial of atorvastatin

  2015cites this paper
• Sodium nitrite attenuates MMP-9 production by endothelial cells and may explain similar effects of atorvastatin

  2015cites this paper
• Atorvastatin and sildenafil decrease vascular TGF-β levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertension

  2015cites this paper
• Membrane Cholesterol Modulates LOX-1 Shedding in Endothelial Cells

  2015cites this paper
• Matrix metalloproteases as a pharmacological target in cardiovascular diseases.

  2015cites this paper
• Effect of Simvastatin on MMPs and TIMPs in Human Brain Endothelial Cells and Experimental Stroke

  2015cites this paper
• Statins as Pleiotropic Modifiers of Vascular Oxidative Stress and Inflammation

  2015cites this paper
• Molecular mechanism underlying the anticancer effect of simvastatin on MDA-MB-231 human breast cancer cells.

  2015cites this paper
• Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis

  2014cites this paper
• Simvastatin induces NFκB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells.

  2014cites this paper
• Association of matrix metalloproteinase-9 C1562T polymorphism and coronary artery disease: a meta-analysis

  2014cites this paper
• A Study of Effects on MMP14 Transcriptional Regulation and Angiogenesis by Hypoxia and Statins

  2014cites this paper
• The effects of previous statin treatment on plasma matrix metalloproteinase-9 level in Chinese stroke patients undergoing thrombolysis.

  2014cites this paper
• Efeitos inibitórios de drogas ativadoras da via NO-GMP cíclico sobre a produção estimulada de MMP-9 em células endoteliais

  2014cites this paper
• Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression.

  2013cites this paper
• Biocompatibility studies of low temperature nitrided and collagen-I coated AISI 316L austenitic stainless steel

  2013cites this paper
• Statins induce biochemical changes in the Achilles tendon after chronic treatment.

  2013cites this paper
• Nitric oxide attenuates matrix metalloproteinase-9 production by endothelial cells independent of cGMP- or NFκB-mediated mechanisms

  2013cites this paper
• Matrix Metalloproteinases: A Target in In-Stent Restenosis?

  2013cites this paper
• Atorvastatin reduces myocardial fibrosis in a rat model with post‐myocardial infarction heart failure by increasing the matrix metalloproteinase‐2/tissue matrix metalloproteinase inhibitor‐2 ratio

  2013cites this paper
• Simvastatin therapy decreases MMP‐9 levels in obese women

  2013cites this paper
• Mecanismos moleculares de las estatinas sobre el cáncer

  2012cites this paper
• Atorvastatin hemmer aktiviteten av cysteinproteaser og stimulerer sekresjonen av MMP-9

  2012influential citation
• Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy

  2012cites this paper
• Oral Contraceptive Containing Chlormadinone Acetate and Ethinylestradiol Reduces Plasma Concentrations of Matrix Metalloproteinase‐2 in Women with Polycystic Ovary Syndrome

  2012cites this paper
• Comprehensive Evaluation of the Effects of Enalapril on Matrix Metalloproteinases Levels in Hypertension

  2012influential citation
• Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women.

  2012cites this paper
• Associations of markers of inflammation and coagulation with delirium during critical illness

  2012cites this paper
• Elevated plasma levels of TIMP-1 in patients with rotator cuff tear

  2012cites this paper
• Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target.

  2012cites this paper
• Circulating matrix metalloproteinases and their inhibitors in hypertension.

  2012cites this paper